Tilmicosin is primarily used for the prevention and treatment of pneumonia in livestock (caused by infections such as Actinobacillus pleuropneumoniae, Pasteurella, and mycoplasma), avian mycoplasmosis, and mastitis in lactating animals.

Mechanism of Action: It reversibly binds to the 50S subunit of bacterial ribosomes, blocking transpeptidation and mRNA translocation, thereby inhibiting bacterial protein synthesis and exerting bacteriostatic effects.

3 invention patents • Highest production volume • Purity 99%PharmacodynamicsTilmicosin is an animal-specific semi-synthetic macrolide antibacterial agent. Its antibacterial activity is similar to tylosin, with strong inhibitory effects against Gram-positive bacteria, partial Gram-negative bacteria, mycoplasma, spirochetes, etc. Notably, its antibacterial activity against Actinobacillus pleuropneumoniae, Pasteurella, and avian/livestock mycoplasma is stronger than tylosin. 95% of Pasteurella haemolytica strains are sensitive to this product.PharmacokineticsAfter administration, it is rapidly absorbed, characterized by strong tissue penetration and a large volume of distribution (>2 L/kg). It achieves particularly high drug concentrations in tissues such as the lungs and mammary glands, with a prolonged duration of action. The half-life can reach 1–2 days. In dairy cows, peak plasma concentration is attained within 1 hour after administration, and milk concentrations remain bacterially active for 3 days.ToxicologyTilmicosin has strong irritancy. Intramuscular injection may cause local inflammation, so deep intramuscular injection is recommended. It exhibits certain toxic effects on the cardiovascular system, including tachycardia and reduced contractility, leading to negative inotropic effects. Therefore, intravenous injection of this product is strictly prohibited.